Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial

BACKGROUND: Raltegravir is an integrase inhibitor approved for use in adults and children with HIV-1 infection, but there are no data on the long-term use of this medication in children. We aimed to assess the long-term safety, tolerability, pharmacokinetics, and efficacy of multiple raltegravir for...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet HIV
Egile Nagusiak: Nachman, Sharon, Alvero, Carmelita, Teppler, Hedy, Homony, Brenda, Rodgers, Anthony J, Graham, Bobbie L, Fenton, Terence, Frenkel, Lisa M, Browning, Renee S, Hazra, Rohan, Wiznia, Andrew A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6537590/
https://ncbi.nlm.nih.gov/pubmed/30527329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(18)30257-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak